½ÃÀ庸°í¼­
»óǰÄÚµå
1805992

MMR ¹é½Å ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2031³â)

MMR Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Lucintel | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ MMR ¹é½Å ½ÃÀå Àü¸ÁÀº º´¿ø ¹× ÀÇ·á±â°ü, ¹é½Å ¼¾ÅÍ ¹× °øÁߺ¸°Ç Ŭ¸®´Ð, ¼Ò¾Æ°ú ¹× ¹Î°£ ÀÇ·á Ŭ¸®´ÐÀÇ ±âȸ·Î ÀÎÇØ À¯¸ÁÇÑ °ÍÀ¸·Î Àü¸ÁµÇ°í ÀÖ½À´Ï´Ù. ¼¼°è MMR ¹é½Å ½ÃÀåÀº 2025-2031³â ¿¬Æò±Õ 8.3%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ´ëºÎºÐÀÇ ±¹°¡¿¡¼­ MMR ¹é½ÅÀÌ ¼Ò¾Æ±â Á¤±â Á¢Á¾ ÀÏÁ¤¿¡ Æ÷ÇԵǾî ÀÖ´Ù´Â Á¡, ÇØ¿Ü ¿©ÇàÀ¸·Î ÀÎÇÑ ±¹°æ °£ Áý´Ü À̵¿ÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡, ¹é½ÅÀÇ ¾ÈÀü¼º°ú ´ëÁß ±³À°¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù.

  • LucintelÀÇ ¿¹Ãø¿¡ µû¸£¸é, À¯Çüº°·Î´Â ´ÜÀϰ¡ ¹é½ÅÀº ¿¹Ãø ±â°£ µ¿¾È ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • ¿ëµµº°·Î´Â º´¿ø ¹× ÀÇ·á±â°üÀÌ ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • Áö¿ªº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

MMR ¹é½Å ½ÃÀåÀÇ »õ·Î¿î Æ®·»µå

¼¼°è MMR ¹é½Å ½ÃÀåÀº ÁøÈ­ÇÏ´Â °øÁߺ¸°Ç ¼ö¿ä, ±â¼ú ¹ßÀü, »çȸÀû ¿äÀο¡ ´ëÀÀÇÏ´Â »õ·Î¿î Æ®·»µåÀÇ ÃâÇöÀ¸·Î Å« º¯È­ÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¹é½Å À¯ÅëÀ» À籸¼ºÇϰí, Á¢±Ù¼ºÀ» °³¼±Çϰí, ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ÁÖÀú¿Í °¡°Ý µîÀÇ ¹®Á¦¸¦ ÇØ°áÇÔÀ¸·Î½á Àü ¼¼°èÀûÀ¸·Î º¸´Ù È¿°úÀûÀÌ°í ±¤¹üÀ§ÇÑ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

  • ¹é½Å Àǹ«È­ ¹× ±ÔÁ¦ °­È­: ¼¼°è °¢±¹ Á¤ºÎ´Â MMR ¹é½Å Á¢Á¾À» Àǹ«È­Çϰí ÀÖÀ¸¸ç, ÃëÇÐ ¹× ¿©Çà ½Ã ¿¹¹æÁ¢Á¾À» Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ƯÈ÷ ¼±Áø±¹¿¡¼­ ¹é½Å Á¢Á¾·üÀ» Å©°Ô ²ø¾î¿Ã¸®°í ÀÖ½À´Ï´Ù. ¹ßº´À» ¿¹¹æÇϰí Áý´Ü ¸é¿ªÀ» È®º¸Çϱâ À§Çؼ­´Â º¸´Ù °­·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ½ÃÇà Á¤Ã¥ÀÌ ÇʼöÀûÀÔ´Ï´Ù.
  • ¹é½Å ¾ÈÀü¼º ¹× ´ëÁß ±³À°¿¡ ´ëÇÑ °­Á¶: °øÁߺ¸°Ç ´ç±¹Àº Ç¥ÀûÈ­µÈ ±³À° Ä·ÆäÀÎÀ» ÅëÇØ ¹é½Å¿¡ ´ëÇÑ À߸øµÈ Á¤º¸¿Í Á¢Á¾¿¡ ´ëÇÑ ÁÖÀú¸¦ ¾ø¾Ö±â À§ÇÑ ³ë·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¹é½ÅÀÇ ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á°¡ ³ôÀº Áö¿ªµµ Àֱ⠶§¹®¿¡ ³ôÀº Á¢Á¾·üÀ» À¯ÁöÇϱâ À§Çؼ­´Â Åõ¸í¼º, °úÇÐÀû ¼ÒÅë, Áö¿ª»çȸ¿ÍÀÇ ¼ÒÅëÀ» ´õ¿í Áß¿ä½ÃÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.
  • ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ ¼¼°è È®´ë: MMR ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥À» ÁßÀú¼Òµæ ±¹°¡, ƯÈ÷ ¾ÆÇÁ¸®Ä«¿Í ¾Æ½Ã¾Æ·Î È®´ëÇÏ·Á´Â ¿òÁ÷ÀÓÀÌ È°¹ßÇØÁö°í ÀÖ½À´Ï´Ù. ±¹Á¦±â±¸¿Í °¢±¹ Á¤ºÎ´Â ¿¹¹æÁ¢Á¾ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â Áö¿ª¿¡¼­ ¹é½Å Á¢Á¾À» È®´ëÇÏ°í ¿¹¹æ °¡´ÉÇÑ Áúº´ÀÇ ºÎ´ãÀ» Àü ¼¼°èÀûÀ¸·Î ÁÙÀ̱â À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù.
  • È¥ÇÕ¹é½Å ¹× °³·®Çü ¹é½Å: ¹é½Å °³¹ßÀÚµéÀº ¼öµÎ(¼öµÎ)¿Í °°Àº ´Ù¸¥ ¼Ò¾Æ ¹é½Å¿¡ MMRÀ» Ãß°¡ÇÑ È¥ÇÕ¹é½ÅÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¥ÇÕ ¹é½ÅÀº º¸È£ÀÚ¿¡°Ô ´õ Æí¸®Çϰí, ¿¹¹æÁ¢Á¾ ¼øÀÀµµ¸¦ ³ôÀ̰í, ÀÇ·áºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¹é½Å Àü´Þ ±â¼úÀÇ ¹ßÀü: ¹«Ä§ÁÖ»ç ½Ã½ºÅÛ, ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡ µî »õ·Î¿î ¹é½Å Àü´Þ ±â¼úÀÌ MMR ¹é½Å ½ÃÀå¿¡ º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¹é½ÅÀÇ ¼ö¿ë¼ºÀ» Çâ»ó½Ã۰í, Áֻ翡 ´ëÇÑ ÅëÁõ°ú µÎ·Á¿òÀ» °¨¼Ò½Ã۸ç, Á¢±ÙÇϱ⠾î·Á¿î Áö¿ª¿¡¼­ÀÇ ¹é½Å Á¢Á¾ Ä·ÆäÀÎÀ» °£¼ÒÈ­ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ÀÌ·¯ÇÑ »õ·Î¿î Æ®·»µå´Â ¹é½Å Á¢Á¾À» °³¼±Çϰí, Á¢±Ù¼ºÀ» È®´ëÇϸç, ¹é½Å Á¢Á¾¿¡ ´ëÇÑ °ÅºÎ°¨À» ÇØ¼ÒÇÔÀ¸·Î½á MMR ¹é½ÅÀÇ »óȲÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× Á¦Á¶¾÷ü°¡ Áúº´ ¿¹¹æ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ Çù·ÂÇÏ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ Ãß¼¼´Â Àü ¼¼°è ¿¹¹æÁ¢Á¾ Ȱµ¿À» °­È­Çϰí Àü ¼¼°è È«¿ª, À¯Ç༺ÀÌÇϼ±¿° ¹× dzÁø ¹ß»ý·üÀ» °¨¼Ò½Ãų °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

MMR ¹é½Å ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

¼¼°è MMR ¹é½Å ½ÃÀåÀº »çȸÀû ÀÎ½Ä °³¼±, ¹é½Å ±â¼ú ¹ßÀü, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ ÁøÈ­ µîÀ» ¹è°æÀ¸·Î Áö³­ ¸î ³â µ¿¾È ¸î °¡Áö Áß¿äÇÑ Ãß¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº È«¿ª, À¯Ç༺ ÀÌÇϼ±¿°, dzÁø°ú °°Àº ¿¹¹æ °¡´ÉÇÑ Áúº´À» ÅðÄ¡Çϱâ À§ÇÑ ³ë·Â¿¡ ÀÖ¾î °úÁ¦¿Í ±âȸ¸¦ ¸ðµÎ ¹Ý¿µÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ÃÖ±Ù À¯Çà Ãß¼¼¿Í ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ¸Á¼³ÀÓ¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.

  • ¹é½Å Àǹ«È­ ¹× ±ÔÁ¦ °­È­: µ¶Àϰú ¹Ì±¹À» Æ÷ÇÔÇÑ ¸¹Àº ±¹°¡¿¡¼­ ÃëÇÐ Àü MMR ¹é½Å Á¢Á¾À» Àǹ«È­ÇÏ´Â µî º¸´Ù ¾ö°ÝÇÑ ¹é½Å Á¢Á¾ ¿ä°ÇÀ» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ º¯°æÀº ƯÈ÷ °íÀ§Çè Áö¿ª¿¡¼­ ´õ ¸¹Àº ¾î¸°À̵éÀÌ ¹é½Å Á¢Á¾À» ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á Àü¿°º´ ¹ß»ýÀ» ¾ïÁ¦ÇÏ°í ´õ ³ôÀº Á¢Á¾·üÀ» ´Þ¼ºÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
  • Àú¼Òµæ ±¹°¡¿¡¼­ÀÇ ¼¼°è ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎ: WHO¿Í GAVI¸¦ Æ÷ÇÔÇÑ ¼¼°èº¸°Ç±â±¸(WHO)¿Í ¼¼°èº¸°Ç±â±¸(GAVI)´Â ÀÇ·á ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÏ´Â Áö¿ª¿¡ MMR ¹é½ÅÀ» Á¦°øÇϱâ À§ÇÑ ³ë·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â Àεµ¿Í ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª°ú °°Àº ±¹°¡¿¡¼­ ´ë±Ô¸ð ¿¹¹æÁ¢Á¾ Ä·ÆäÀÎÀÌ Æ÷ÇԵǸç, È«¿ª°ú dzÁø ¹ß»ý·üÀ» ³·Ãß±â À§ÇØ ¿¹¹æÁ¢Á¾·üÀÌ ³·Àº Áö¿ª¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.
  • ¹é½Å À¯ÅëÀÇ ±â¼úÀû °³¼±: ¹é½ÅÀÇ º¸°ü, ¿î¼Û, ¹è¼Û ¹æ¹ýÀÇ ¹ßÀüÀ¸·Î ¿ÀÁö³ª ³óÃÌ Áö¿ª¿¡¼­µµ MMR ¹é½ÅÀ» ½±°Ô Á¢ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿©±â¿¡´Â ÀúÀÚ¿ø ȯ°æ¿¡¼­ ÄݵåüÀÎ À¯Áö¿Í ¿î¼Û Áß ¹é½ÅÀÇ ¹«°á¼ºÀ» º¸ÀåÇÏ´Â µ¥ ÇʼöÀûÀΠž翭 ³ÃÀå°í, µðÁöÅÐ ÃßÀû ½Ã½ºÅÛ µîÀÇ ±â¼ú Çõ½ÅÀÌ Æ÷ÇԵ˴ϴÙ.
  • Á¢Á¾·ü Çâ»óÀ» À§ÇÑ È¥ÇÕ¹é½Å: MMRV(È«¿ª, º¼°Å¸®, dzÁø, ¼öµÎ) ¹é½Å°ú °°Àº È¥ÇÕ¹é½ÅÀÇ µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹é½ÅÀº ƯÈ÷ À¯¾ÆÀÇ °æ¿ì, º¸´Ù È¿À²ÀûÀÎ Á¢Á¾ ½ºÄÉÁÙÀ» °¡´ÉÇÏ°Ô Çϰí, ÁÖ»ç Ƚ¼ö¸¦ ÁÙ¿© ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¼øÀÀµµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.
  • ¹é½Å Á¢Á¾ °ÅºÎ°¨À» ÇØ¼ÒÇϱâ À§ÇÑ °øÁߺ¸°Ç Ä·ÆäÀÎ: Á¤ºÎ¿Í °øÁߺ¸°Ç ±â°üÀº ¹é½Å ¿Àº¸¿Í ½Î¿ì°í MMR ¹é½Å¿¡ ´ëÇÑ ´ëÁßÀÇ ½Å·Ú¸¦ ³ôÀ̱â À§ÇØ ´ëÁß ±³À° ¹× Ä¿¹Â´ÏÄÉÀ̼ǿ¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¹é½Å Á¢Á¾ÀÇ ¾ÈÀü¼º°ú Á߿伺¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ Ä·ÆäÀÎÀº ¿¹¹æÁ¢Á¾·üÀ» ³ôÀÌ°í ¹ßº´À» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

MMR ¹é½Å ½ÃÀåÀÇ ÃÖ±Ù µ¿ÇâÀº ¹é½Å Á¢±Ù¼º, ±â¼ú Çõ½Å, ±ÔÁ¦ °­È­¿¡ ÀÖ¾î Å« ÁøÀüÀ» º¸À̰í ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ¿Í ±¹Á¦±â±¸°¡ ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ³ë·ÂÀ» °­È­ÇÏ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ ¹ßÀüÀº Àü ¼¼°è ¿¹¹æÁ¢Á¾·üÀ» ³ôÀÌ°í ¿¹¹æ °¡´ÉÇÑ Áúº´ÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

  • ¹è°æ°ú ºÐ·ù
  • °ø±Þ¸Á

Á¦3Àå ½ÃÀå µ¿Çâ°ú ¿¹Ãø ºÐ¼®

  • °Å½Ã°æÁ¦ µ¿Çâ°ú ¿¹Ãø
  • ¾÷°è ÃËÁø¿äÀΰú °úÁ¦
  • PESTLE ºÐ¼®
  • ƯÇ㠺м®
  • ±ÔÁ¦ ȯ°æ

Á¦4Àå ¼¼°èÀÇ MMR ¹é½Å ½ÃÀå : À¯Çüº°

  • °³¿ä
  • ¸Å·Â ºÐ¼® : À¯Çüº°
  • 1°¡ ¹é½Å : µ¿Çâ°ú ¿¹Ãø(2019-2031)
  • 3°¡ ¹é½Å: µ¿Çâ°ú ¿¹Ãø(2019-2031³â)
  • 4°¡ ¹é½Å : µ¿Çâ°ú ¿¹Ãø(2019-2031³â)

Á¦5Àå ¼¼°èÀÇ MMR ¹é½Å ½ÃÀå : À¯Åë ä³Îº°

  • °³¿ä
  • ¸Å·Â ºÐ¼® : À¯Åë ä³Îº°
  • º´¿ø ¹× ÀÇ·á±â°ü : µ¿Çâ°ú ¿¹Ãø(2019-2031³â)
  • ¹é½Å ¼¾ÅÍ ¹× °øÁßÀ§»ý Ŭ¸®´Ð : µ¿Çâ°ú ¿¹Ãø(2019-2031³â)
  • ¼Ò¾Æ°ú ¹× ¹Î°£ ÀÇ·á Ŭ¸®´Ð : µ¿Çâ°ú ¿¹Ãø(2019-2031³â)

Á¦6Àå Áö¿ª ºÐ¼®

  • °³¿ä
  • ¼¼°èÀÇ MMR ¹é½Å ½ÃÀå : Áö¿ªº°

Á¦7Àå ºÏ¹ÌÀÇ MMR ¹é½Å ½ÃÀå

  • °³¿ä
  • ºÏ¹ÌÀÇ MMR ¹é½Å ½ÃÀå : À¯Çüº°
  • ºÏ¹ÌÀÇ MMR ¹é½Å ½ÃÀå : À¯Åë ä³Îº°
  • ¹Ì±¹ÀÇ MMR ¹é½Å ½ÃÀå
  • ¸ß½ÃÄÚÀÇ MMR ¹é½Å ½ÃÀå
  • ij³ª´ÙÀÇ MMR ¹é½Å ½ÃÀå

Á¦8Àå À¯·´ÀÇ MMR ¹é½Å ½ÃÀå

  • °³¿ä
  • À¯·´ÀÇ MMR ¹é½Å ½ÃÀå : À¯Çüº°
  • À¯·´ÀÇ MMR ¹é½Å ½ÃÀå : À¯Åë ä³Îº°
  • µ¶ÀÏÀÇ MMR ¹é½Å ½ÃÀå
  • ÇÁ¶û½ºÀÇ MMR ¹é½Å ½ÃÀå
  • ½ºÆäÀÎÀÇ MMR ¹é½Å ½ÃÀå
  • ÀÌÅ»¸®¾ÆÀÇ MMR ¹é½Å ½ÃÀå
  • ¿µ±¹ÀÇ MMR ¹é½Å ½ÃÀå

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ MMR ¹é½Å ½ÃÀå

  • °³¿ä
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ MMR ¹é½Å ½ÃÀå : À¯Çüº°
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ MMR ¹é½Å ½ÃÀå : À¯Åë ä³Îº°
  • ÀϺ»ÀÇ MMR ¹é½Å ½ÃÀå
  • ÀεµÀÇ MMR ¹é½Å ½ÃÀå
  • Áß±¹ÀÇ MMR ¹é½Å ½ÃÀå
  • Çѱ¹ÀÇ MMR ¹é½Å ½ÃÀå
  • Àεµ³×½Ã¾ÆÀÇ MMR ¹é½Å ½ÃÀå

Á¦10Àå ±âŸ Áö¿ª(ROW)ÀÇ MMR ¹é½Å ½ÃÀå

  • °³¿ä
  • ºÏ¹ÌÀÇ MMR ¹é½Å ½ÃÀå : À¯Çüº°
  • ºÏ¹ÌÀÇ MMR ¹é½Å ½ÃÀå : À¯Åë ä³Îº°
  • Áßµ¿ÀÇ MMR ¹é½Å ½ÃÀå
  • ³²¹ÌÀÇ MMR ¹é½Å ½ÃÀå
  • ¾ÆÇÁ¸®Ä«ÀÇ MMR ¹é½Å ½ÃÀå

Á¦11Àå °æÀï ºÐ¼®

  • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
  • ¿î¿µ ÅëÇÕ
  • PorterÀÇ Five Forces ºÐ¼®
    • °æÀï ±â¾÷°£ °æÀï °ü°è
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • °ø±Þ¾÷üÀÇ ±³¼··Â
    • ´ëüǰÀÇ À§Çù
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ½ÃÀå Á¡À¯À² ºÐ¼®

Á¦12Àå ±âȸ¿Í Àü·« ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¼ºÀå ±âȸ ºÐ¼®
    • ¼ºÀå ±âȸ : À¯Çüº°
    • ¼ºÀå ±âȸ : À¯Åë ä³Îº°
  • ¼¼°è MMR ¹é½Å ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ
  • Àü·« ºÐ¼®
    • ½ÅÁ¦Ç° °³¹ß
    • ÀÎÁõ ¹× ¶óÀ̼±½Ì
    • ÀμöÇÕº´(M&A), °è¾à, Á¦ÈÞ ¹× ÇÕÀÛÅõÀÚ(JV)

Á¦13Àå ¹ë·ùüÀÎ ÁÖ¿ä ±â¾÷ °³¿ä

  • Competitive Analysis
  • Merck & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • Biological E. Limited

Á¦14Àå ºÎ·Ï

  • ±×¸² ¸®½ºÆ®
  • Ç¥ ¸®½ºÆ®
  • ºÐ¼® ¹æ¹ý
  • ¸éÃ¥»çÇ×
  • ÀúÀÛ±Ç
  • ¾à¾î¿Í ±â¼ú ´ÜÀ§
  • Lucintel¿¡ ´ëÇØ
  • ¹®ÀÇ
LSH

The future of the global MMR vaccine market looks promising with opportunities in hospitals and healthcare institutions, vaccine centers and public health clinics, and pediatric and private healthcare clinics. The global MMR vaccine market is expected to grow with a CAGR of 8.3% from 2025 to 2031. The major drivers for this market are that the MMR vaccine is included in routine childhood vaccination schedules in most countries, international travel has led to an increase in the movement of populations across borders, and there is a focus on vaccine safety and public education.

  • Lucintel forecasts that, within the type category, monovalent is expected to witness higher growth over the forecast period.
  • Within the application category, hospitals and healthcare institutions are expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the MMR Vaccine Market

The global MMR vaccine market is undergoing significant transformations as new trends emerge in response to evolving public health needs, technological advancements, and social factors. These trends are reshaping vaccine distribution, improving accessibility, and addressing challenges like vaccine hesitancy and affordability, ensuring more effective and widespread immunization programs globally.

  • Increase in vaccine mandates and legislation: Governments worldwide are strengthening MMR vaccine mandates, requiring immunization for school enrollment and travel. This trend is significantly boosting vaccination rates, especially in developed nations. Stronger regulatory frameworks and enforcement policies are critical to preventing outbreaks and ensuring herd immunity.
  • Focus on vaccine safety and public education: Public health authorities are intensifying efforts to combat vaccine misinformation and hesitancy through targeted education campaigns. As concerns over vaccine safety persist in some regions, greater emphasis on transparency, scientific communication, and community engagement is essential to maintaining high vaccination coverage.
  • Global expansion of immunization programs: There is a growing effort to extend MMR vaccination programs to low- and middle-income countries, especially in Africa and Asia. International organizations and governments are working together to expand access to vaccines in underserved regions, reducing the burden of preventable diseases globally.
  • Combination vaccines and improved formulations: Vaccine developers are working on combination vaccines that include MMR alongside other childhood vaccines like varicella (chickenpox). These combination vaccines are more convenient for parents, increase vaccination adherence, and reduce healthcare costs, which can be particularly beneficial in regions with limited resources.
  • Technological advancements in vaccine delivery: New vaccine delivery technologies, such as needle-free injection systems and micro-needle patches, are gaining traction in the MMR vaccine market. These innovations are expected to improve vaccine acceptance, reduce pain or fear of injections, and streamline vaccination campaigns in hard-to-reach areas.

These emerging trends are transforming the MMR vaccine landscape by improving vaccine delivery, expanding access, and addressing vaccine hesitancy. As governments, healthcare providers, and manufacturers collaborate to tackle the challenges of disease prevention, these trends promise to enhance global immunization efforts and reduce the incidence of measles, mumps, and rubella worldwide.

Recent Developments in the MMR Vaccine Market

The global MMR vaccine market has seen several key developments in recent years, driven by increased public awareness, advancements in vaccine technology, and evolving regulatory frameworks. These developments reflect both challenges and opportunities in the effort to combat preventable diseases like measles, mumps, and rubella, particularly in the face of recent outbreaks and growing vaccine hesitancy.

  • Stronger vaccine mandates and regulations: Many countries, including Germany and the U.S., have implemented stricter vaccination requirements, such as mandatory MMR vaccines for school enrollment. These regulatory changes are aimed at curbing outbreaks and achieving higher vaccination coverage, ensuring that more children are vaccinated, especially in high-risk regions.
  • Global vaccination campaigns in low-income countries: Global health organizations, including the WHO and GAVI, have ramped up efforts to deliver MMR vaccines to underserved regions. This includes large-scale immunization campaigns in countries like India and parts of Africa, focusing on areas with low vaccine coverage to reduce the incidence of measles and rubella.
  • Technological improvements in vaccine distribution: Advances in vaccine storage, transportation, and delivery methods are improving MMR vaccine accessibility in remote and rural areas. This includes innovations like solar-powered refrigerators and digital tracking systems, which are essential for maintaining the cold chain in low-resource settings and ensuring the integrity of vaccines during transportation.
  • Combination vaccines for improved coverage: The introduction of combination vaccines, such as the MMRV (measles, mumps, rubella, and varicella) vaccine, is gaining momentum. These vaccines allow for more efficient vaccination schedules, particularly for young children, reducing the number of injections required and increasing adherence to vaccination programs.
  • Public health campaigns to address vaccine hesitancy: Governments and public health agencies are focusing on public education and communication to combat vaccine misinformation and improve public confidence in MMR vaccines. Campaigns aimed at increasing awareness about the safety and importance of vaccination are critical to boosting coverage rates and preventing outbreaks.

Recent developments in the MMR vaccine market highlight significant progress in vaccine access, technological innovation, and regulatory enforcement. As governments and global organizations strengthen vaccination efforts, these developments are expected to play a crucial role in increasing global immunization rates and reducing the burden of preventable diseases.

Strategic Growth Opportunities in the MMR Vaccine Market

The global MMR vaccine market is poised for growth, driven by opportunities across key applications such as pediatric vaccination, public health campaigns, and international outreach programs. By focusing on these areas, the market can expand its reach and address vaccine gaps in high-risk populations, especially in developing countries and underserved communities.

  • Expansion of pediatric immunization programs: As childhood immunization remains a key priority for global health organizations, there is significant growth potential in the pediatric segment. Strengthening national immunization programs and reaching underserved areas will increase vaccine uptake and prevent outbreaks, especially in regions with high birth rates.
  • Global vaccination campaigns in developing countries: Significant opportunities exist in expanding MMR vaccine access to low-income and middle-income countries, particularly in Africa and Asia. Organizations like GAVI and UNICEF are working to reduce vaccine inequity, providing funding and logistics support to ensure vaccines reach remote and underserved populations.
  • Focus on vaccine safety and public education initiatives: Educational campaigns aimed at raising awareness about the safety and efficacy of the MMR vaccine represent a growth opportunity, especially in regions where vaccine hesitancy is high. Addressing misinformation through targeted campaigns can help increase vaccination rates and improve public confidence in the vaccine.
  • Combination vaccines for increased adoption: Combination vaccines that include MMR along with other essential vaccines, such as chickenpox (varicella) and hepatitis B, offer a compelling growth opportunity. These vaccines reduce the number of injections required and improve compliance with vaccination schedules, particularly for young children.
  • Strengthening healthcare infrastructure in developing regions: Growth opportunities also lie in improving the healthcare infrastructure, particularly in rural and underserved regions. Expanding access to MMR vaccines through mobile clinics, community health workers, and improved cold chain logistics will help improve vaccination coverage and prevent outbreaks in these areas.

Strategic growth opportunities in the MMR vaccine market are primarily driven by expanding access in developing countries, strengthening pediatric vaccination programs, and addressing vaccine hesitancy. As efforts focus on improving accessibility and education, the market has the potential to significantly reduce the burden of measles, mumps, and rubella worldwide.

MMR Vaccine Market Driver and Challenges

The global MMR vaccine market is influenced by a range of drivers and challenges that affect vaccination rates, accessibility, and public health outcomes. These include technological advancements, economic factors, and regulatory policies, as well as challenges like vaccine hesitancy, logistical hurdles, and disparities in healthcare access.

The factors responsible for driving the MMR vaccine market include:

1. Increased government and public health support: Government mandates, such as vaccination requirements for school enrollment, and support from global health organizations like WHO and UNICEF are strong drivers for the MMR vaccine market. These initiatives help expand vaccine coverage, reduce preventable diseases, and ensure higher immunization rates worldwide.

2. Rising awareness of vaccine-preventable diseases: As measles outbreaks increase in certain regions, there is greater awareness of the importance of MMR vaccination. Public health campaigns are educating communities about the risks of vaccine-preventable diseases, driving higher vaccine adoption rates, particularly in developed nations.

3. Improved vaccine accessibility and distribution: Advances in vaccine delivery systems, including better cold chain logistics and digital tracking, are improving access to MMR vaccines, especially in remote and underserved regions. This is helping ensure that vaccines reach populations at risk of preventable diseases.

4. Introduction of combination vaccines: The development and adoption of combination vaccines, such as MMRV (measles, mumps, rubella, and varicella), are helping increase vaccination coverage by reducing the number of injections needed for children. These vaccines simplify immunization schedules, making it easier for parents to comply with vaccination recommendations.

5. International collaboration and funding: Global organizations like GAVI, UNICEF, and the WHO are providing significant funding and logistical support to ensure vaccines reach populations in developing countries. These collaborations are essential for addressing vaccine inequities and improving global immunization rates.

The challenges in the MMR vaccine market are:

1. Vaccine hesitancy and misinformation: Vaccine hesitancy, fueled by misinformation and distrust in vaccines, remains a significant challenge, particularly in high-income countries. Overcoming this challenge requires targeted public education campaigns and transparent communication to build public confidence in the safety and efficacy of the MMR vaccine.

2. Logistical and infrastructure barriers: In many developing regions, inadequate healthcare infrastructure, poor cold chain management, and limited access to healthcare services hinder the effective distribution and delivery of MMR vaccines. These logistical challenges need to be addressed to ensure vaccines reach rural and hard-to-reach areas.

3. Disparities in vaccine access: Disparities in vaccine access, particularly in low- and middle-income countries, continue to impede progress in achieving global immunization goals. Factors such as poverty, conflict, and weak healthcare systems exacerbate these challenges, highlighting the need for targeted intervention and support to reach underserved populations.

The drivers and challenges shaping the global MMR vaccine market reflect a dynamic interplay of factors that influence vaccine adoption, accessibility, and public health outcomes. While increased government support and improved vaccine delivery systems are driving growth, addressing vaccine hesitancy, logistical barriers, and access disparities remains crucial to achieving universal immunization coverage.

List of MMR Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, MMR vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products and technologies, reduce production costs, and expand their customer base. Some of the MMR vaccine companies profiled in this report include:

  • Merck & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • Biological E. Limited

MMR Vaccine Market by Segment

The study includes a forecast for the global MMR vaccine market by type, distribution channel, and region.

MMR Vaccine Market by Type [Value from 2019 to 2031]:

  • Monovalent
  • Trivalent
  • Tetravalent

MMR Vaccine Market by Distribution Channel [Value from 2019 to 2031]:

  • Hospitals and Healthcare Institutions
  • Vaccine Centers and Public Health Clinics
  • Pediatric and Private Healthcare Clinics

MMR Vaccine Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the MMR Vaccine Market

Recent developments in the global MMR vaccine market reflect ongoing efforts to increase vaccination coverage and combat rising cases of preventable diseases. Governments, healthcare providers, and vaccine manufacturers are focusing on expanding access, improving vaccine efficacy, and addressing vaccine hesitancy. In regions like the United States, China, Germany, India, and Japan, key advancements are shaping the future of the MMR vaccine landscape, particularly in light of recent outbreaks.

  • United States: In the U.S., the MMR vaccine market has seen robust growth due to increased awareness and government mandates, with widespread vaccination programs in schools. Recent efforts focus on addressing vaccine hesitancy, particularly in certain communities, through targeted public health campaigns. Despite high vaccination coverage, localized outbreaks of measles have highlighted the need for continued vigilance and education around the importance of vaccination, ensuring high immunization rates.
  • China: China has significantly improved its vaccination infrastructure and coverage, with the MMR vaccine being a part of its routine immunization program. The government has been working to strengthen vaccine supply chains and expand access in rural areas. Recent efforts focus on addressing concerns over vaccine safety and increasing public trust. Increased government funding for vaccination programs is also helping expand coverage, reducing the risk of outbreaks.
  • Germany: Germany has made strides in improving MMR vaccination rates, with a renewed focus on strengthening public health policies. The country recently implemented stricter vaccination requirements, mandating the MMR vaccine for school enrollment to address rising cases of measles. Germany's efforts include educational campaigns to boost public confidence and reduce vaccine hesitancy, particularly in areas with lower vaccination rates. The government's response to recent outbreaks has highlighted the importance of universal vaccination.
  • India: In India, MMR vaccine coverage has been increasing as part of the national immunization program. The government is focusing on expanding access to vaccines in rural and underserved areas, where healthcare infrastructure is limited. Additionally, India is tackling vaccine hesitancy through community-based programs and educational initiatives. With its large population and high birth rate, India represents a significant market for MMR vaccines, and the government is actively working to reach the remaining unvaccinated groups.
  • Japan: Japan has maintained high MMR vaccination coverage, but concerns over vaccine safety and side effects have led to public hesitancy in certain regions. The government has responded with educational campaigns to address fears and ensure higher vaccination rates. Japan's national immunization program offers MMR vaccines to children, and recent reforms focus on streamlining vaccine delivery to increase accessibility, particularly in remote areas. Public-private partnerships are also strengthening the distribution network.

Features of the Global MMR Vaccine Market

  • Market Size Estimates: MMR vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: MMR vaccine market size by type, distribution channel, and region in terms of value ($B).
  • Regional Analysis: MMR vaccine market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the MMR vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the MMR vaccine market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the MMR vaccine market by type (monovalent, trivalent, and tetravalent), distribution channel (hospitals and healthcare institutions, vaccine centers and public health clinics, and pediatric and private healthcare clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global MMR Vaccine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Monovalent: Trends and Forecast (2019-2031)
  • 4.4 Trivalent: Trends and Forecast (2019-2031)
  • 4.5 Tetravalent: Trends and Forecast (2019-2031)

5. Global MMR Vaccine Market by Distribution Channel

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Distribution Channel
  • 5.3 Hospitals and Healthcare Institutions: Trends and Forecast (2019-2031)
  • 5.4 Vaccine Centers and Public Health Clinics: Trends and Forecast (2019-2031)
  • 5.5 Pediatric and Private Healthcare Clinics: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global MMR Vaccine Market by Region

7. North American MMR Vaccine Market

  • 7.1 Overview
  • 7.2 North American MMR Vaccine Market by Type
  • 7.3 North American MMR Vaccine Market by Distribution Channel
  • 7.4 United States MMR Vaccine Market
  • 7.5 Mexican MMR Vaccine Market
  • 7.6 Canadian MMR Vaccine Market

8. European MMR Vaccine Market

  • 8.1 Overview
  • 8.2 European MMR Vaccine Market by Type
  • 8.3 European MMR Vaccine Market by Distribution Channel
  • 8.4 German MMR Vaccine Market
  • 8.5 French MMR Vaccine Market
  • 8.6 Spanish MMR Vaccine Market
  • 8.7 Italian MMR Vaccine Market
  • 8.8 United Kingdom MMR Vaccine Market

9. APAC MMR Vaccine Market

  • 9.1 Overview
  • 9.2 APAC MMR Vaccine Market by Type
  • 9.3 APAC MMR Vaccine Market by Distribution Channel
  • 9.4 Japanese MMR Vaccine Market
  • 9.5 Indian MMR Vaccine Market
  • 9.6 Chinese MMR Vaccine Market
  • 9.7 South Korean MMR Vaccine Market
  • 9.8 Indonesian MMR Vaccine Market

10. ROW MMR Vaccine Market

  • 10.1 Overview
  • 10.2 ROW MMR Vaccine Market by Type
  • 10.3 ROW MMR Vaccine Market by Distribution Channel
  • 10.4 Middle Eastern MMR Vaccine Market
  • 10.5 South American MMR Vaccine Market
  • 10.6 African MMR Vaccine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Distribution Channel
  • 12.3 Emerging Trends in the Global MMR Vaccine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Merck & Co.
    • Company Overview
    • MMR Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 GlaxoSmithKline plc
    • Company Overview
    • MMR Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Pfizer Inc.
    • Company Overview
    • MMR Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Novartis AG
    • Company Overview
    • MMR Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Biological E. Limited
    • Company Overview
    • MMR Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦